Bristol-Myers Stock Tumbles; Celgene Must Divest Psoriasis Drug Otezla Ahead Of Merger - Investor's Business Daily
Celgene will have to divest Otezla to satisfy regulators before merging with Bristol-Myers Squibb. Celgene stock and Bristol-Myers stock fell.
View full coverage on Google News